Specifically, combination therapy of miR-143 and miR-506 downregulates the levels of cyclin-dependent kinases (CDK) 1, CDK4, and CDK6 and induces apoptosis in cancer cells, but it does not affect normal lung fibroblasts. Here, CDK4 is linked to cancer.